Showing results (321-330 of 447) with videos related to

Sort By:
Pageof 45
Stroke|September 14, 2020
Risk of Paradoxical Embolism (RoPE)-Estimated Attributable Fraction Correlates With the Benefit of Patent Foramen Ovale Closure: An Analysis of 3 TrialsDavid M Kent, Jeffrey L Saver, Robin Ruthazer, et al.
American Heart Journal|May 22, 2012
Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stentsMichael Billinger, Lorenz Räber, Sarah Hitz, et al.
Trials|March 2, 2011
Randomized clinical trial comparing percutaneous closure of patent foramen ovale (PFO) using the Amplatzer PFO Occluder with medical treatment in patients with cryptogenic embolism (PC-Trial): rationale and designAhmed A Khattab, Stephan Windecker, Peter Jüni, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|September 9, 2010
Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experienceJai-Wun Park, Armando Bethencourt, Horst Sievert, et al.
Circulation. Cardiovascular Interventions|November 22, 2012
Predictors of clinical outcomes in patients with severe aortic stenosis undergoing TAVI: a multistate analysisThomas Pilgrim, Bindu Kalesan, Peter Wenaweser, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|July 7, 2019
Incidence, predictors, and relevance of acute kidney injury in patients undergoing left atrial appendage closure with Amplatzer occluders: a multicentre observational studyAlexander Sedaghat, Vivian Vij, Samuel R Streit, et al.
Heart (British Cardiac Society)|November 10, 2009
Coronary collateral growth by external counterpulsation: a randomised controlled trialSteffen Gloekler, Pascal Meier, Stefano F de Marchi, et al.
Swiss Medical Weekly|January 15, 2016
Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trialZacharenia Kallinikou, Diego Arroyo, Mario Togni, et al.
Circulation|June 12, 2002
Impact of different platelet glycoprotein IIb/IIIa receptor inhibitors among diabetic patients undergoing percutaneous coronary intervention: : Do Tirofiban and ReoPro Give Similar Efficacy Outcomes Trial (TARGET) 1-year follow-upMarco Roffi, David J Moliterno, Bernhard Meier, et al.
JACC. Cardiovascular Interventions|May 26, 2012
Percutaneous management of vascular complications in patients undergoing transcatheter aortic valve implantationStefan Stortecky, Peter Wenaweser, Nicolas Diehm, et al.
Pageof 45